Mar 17, 2022 3:00 am EDT NeoGenomics Announces That Inivata Liquid Biopsy Subsidiary and Collaborators Have Published Clinical Validation Data for RaDaR(TM) Assay in Non-Small Cell Lung Cancer
Mar 2, 2022 4:05 pm EST NeoGenomics To Participate In Multiple Upcoming Institutional Investor Conferences
Feb 23, 2022 7:00 am EST NeoGenomics Reports Full Year Revenue of $484 Million and $126 Million for the Fourth Quarter of 2021
Feb 14, 2022 7:00 am EST NeoGenomics appoints Dr. Shashi Kulkarni, a World-Renowned Oncology Genomics Expert, and Innovator as Chief Scientific Officer
Feb 11, 2022 2:00 am EST NeoGenomics Liquid Biopsy Subsidiary Inivata and Collaborators Publish Positive Results from Prospective Clinical Study of RaDaR(TM) in Head and Neck Squamous Cell Carcinoma
Feb 8, 2022 7:00 am EST NeoGenomics to Participate Virtually in Multiple Upcoming Institutional Investor Conferences
Feb 2, 2022 4:05 pm EST NeoGenomics Schedules its Fourth Quarter and Full Year 2021 Earnings Release for February 23, 2022
Jan 24, 2022 7:00 am EST NeoGenomics First to Partner with Biomarker Collaborative and Deliver Patient Resources Along with Oncology Testing Results
Jan 11, 2022 7:00 am EST NeoGenomics Announces RaDaR(TM) Assay Receives CE Mark and is Submitted for US Reimbursement via the MolDX Program
